

DNDi Intellectual Property Workshop  
4 December 2010  
New Delhi, India

***Framing an innovation platform for neglected diseases R&D:  
From IP management to open innovation***

**Objectives**

- Sharing of various stakeholders' experience of in IP management that ensures innovation and access
- Discuss initiatives and proposals through which sharing and strategic use of intellectual property rights can be made by stakeholders to ensure public health driven innovation and affordable end-products.

**Agenda**

9:00 - 9:10      **Welcome & introduction from Bernard Pécoul, Executive Director, DNDi**

9:10 - 12:30    **Panel 1: Enabling innovation and access – the Indian context and beyond**

**Moderator: German Velasquez, Senior Advisor, Health & Development, South Centre**

Panelists (15 mn each):

**Prof. Sudip Chaudhuri, Indian Institute of Management, Calcutta**  
R&D for development of new drugs for neglected diseases in India

**Dr. Kanikaram Satyanarayana, Sr. Dy. Director-General and Chief,  
Intellectual Property Rights Unit, Indian Council of Medical Research**  
ICMR research funding mechanisms and IP management

10.45 - 11.00    Tea/coffee break

**Loon Gangte, President of Delhi Network of Positive People**  
Patients' perspective for enabling access of health innovations

**Michelle Childs, Director Policy Advocacy, MSF Campaign for  
Access to Essential Medicines**  
De-linking the research costs from the final price of medicines

**Jean-Pierre Paccaud, Business Development Director, DNDi**  
DNDi practice in ensuring innovation and access

Discussion

12.30 - 2.00      **Lunch**

2.00 - 4.00      **Panel 2: Open innovation initiatives – Towards an open source innovation  
platform for neglected diseases**

**Moderator:** Charles Clift, formerly head of the Secretariat of the WHO Commission on Intellectual Property rights, Innovation and Public Health (CIPIH)

**Dr. Anthony So, Director, Program on Global Health and Technology Access, Duke University (20 mn)**

Respondents (10mn each):

**Zakir Thomas, Project Director, Open Source Drug Discovery & Head DG's Technical Cell, CSIR**

**Thomas Bombelles, consultant, Global Challenges Division, World Intellectual Property Organization**

**Chan Park, Legal Adviser, Medicines Patent Pool**

Discussion

4.00 **Wrap-up and conclusions by Charles Clift & Bernard Pécoul**